Display options
Cite
Tabari RG, Marjani A, Ataby OA, et al. Genetic Polymorphism of Cytochrome p450 (2C19) Enzyme in Iranian Turkman Ethnic Group. Oman Med J. 2013;28(4):237-44doi: 10.5001/omj.2013.69.
Tabari, R. G., Marjani, A., Ataby, O. A., Mansourian, A. R., & Samai, N. M. (2013). Genetic Polymorphism of Cytochrome p450 (2C19) Enzyme in Iranian Turkman Ethnic Group. Oman medical journal, 28(4), 237-44. https://doi.org/10.5001/omj.2013.69
Tabari, Robabeh Ghiyas, et al. "Genetic Polymorphism of Cytochrome p450 (2C19) Enzyme in Iranian Turkman Ethnic Group." Oman medical journal vol. 28,4 (2013): 237-44. doi: https://doi.org/10.5001/omj.2013.69
Tabari RG, Marjani A, Ataby OA, Mansourian AR, Samai NM. Genetic Polymorphism of Cytochrome p450 (2C19) Enzyme in Iranian Turkman Ethnic Group. Oman Med J. 2013 Jul;28(4):237-44. doi: 10.5001/omj.2013.69. PMID: 23904915; PMCID: PMC3725252.
Copy Download .nbib Format: NLM
Share it on

Oman Med J. 2013 Jul;28(4):237-44. doi: 10.5001/omj.2013.69.

Genetic Polymorphism of Cytochrome p450 (2C19) Enzyme in Iranian Turkman Ethnic Group.

Oman medical journal

Robabeh Ghiyas Tabari, Abdoljalal Marjani, Ogholdondy Agh Ataby, Azad Reza Mansourian, Nader Mansour Samai

Affiliations

  1. Department of Biochemistry and Biophysics, Metabolic Disorders Research Center, Gorgan Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Golestan province, Iran.

PMID: 23904915 PMCID: PMC3725252 DOI: 10.5001/omj.2013.69

Abstract

OBJECTIVE: Different findings indicate that CYP2C plays a clinical role in determining interindividual and interethnic differences in drug effectiveness. The ethnic differences in the frequency of CYP2C19 mutant alleles continue to be a significant study topic. The aim of the present study was to assess the frequency of allelic variants of CYP2C19 in Turkman ethnic groups and compare them with the frequencies in other ethnic populations.

METHODS: The study group included 140 unrelated healthy ethnic Turkman subject referred to the Health Center. Genotyping of CYP2C19 alleles (CYP2C19*1, CYP2C19*2, and CYP2C19*3 alleles) was carried out by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism technique.

RESULTS: The allele frequency of CYP2C19*1, CYP2C19*2 and CYP2C19*3 were 56.43%, 23.57% and 20%, respectively. The result also showed that 39.7% of subjects expressed the CYP2C19*1/*1 genotype. While 42.1%, 9.3%, 9.3% and 1.4% expressed CYP2C19*1/*2, CYP2C19*1/*3, CYP2C19*2/*2 and CYP2C19*3/*3 genotypes, respectively. The genotype CYP2C19*2/*3 was not expressed in this study population. The findings suggested that 10% of subjects were poor metabolizers by expressing CYP2C19*2/*2 and CYP2C19*3/*3 genotypes. Fifty one percent of subjects were intermediate metabolizers having CYP2C19*1/*2, CYP2C19*2/*3 and CYP2C19*1/*3 genotypes and 37.86% were found to be extensive metabolizers expressing CYP2C19*1/*1 genotype. The frequency of intermediate metabolizers genotype was high (51%) in Turkman ethnic groups.

CONCLUSION: This study showed that the determined allelic variants of CYP2C19 (CYP2C19*2 and CYP2C19*3 mutations) in Turkman ethnic group are comparable to other populations. These findings could be useful for the clinicians in different country to determine optimal dosage and effectiveness of drugs metabolized by this polymorphic enzyme.

Keywords: CYP2C19 genetic polymorphism; Iranian Turkman ethnic group; polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP)

References

  1. Eur J Clin Pharmacol. 2001 Apr;57(1):11-7 - PubMed
  2. Pharmacogenet Genomics. 2009 Feb;19(2):170-9 - PubMed
  3. Pharmacogenetics. 1995 Dec;5(6):358-63 - PubMed
  4. Br J Clin Pharmacol. 1999 Sep;48(3):402-8 - PubMed
  5. Br J Clin Pharmacol. 2008 May;65(5):752-60 - PubMed
  6. Methods Enzymol. 1996;272:210-8 - PubMed
  7. JAMA. 2009 Aug 26;302(8):849-57 - PubMed
  8. Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):1983-4 - PubMed
  9. Clin Pharmacol Ther. 1985 Oct;38(4):402-8 - PubMed
  10. Croat Med J. 2003 Aug;44(4):425-8 - PubMed
  11. Clin Pharmacol Ther. 1995 Jun;57(6):656-61 - PubMed
  12. Br J Clin Pharmacol. 2003 Dec;56(6):653-7 - PubMed
  13. N Engl J Med. 2009 Jan 22;360(4):363-75 - PubMed
  14. Fundam Clin Pharmacol. 2003 Feb;17(1):27-41 - PubMed
  15. Eur J Clin Pharmacol. 2005 Aug;61(7):491-7 - PubMed
  16. J Biol Chem. 1994 Jun 3;269(22):15419-22 - PubMed
  17. Br J Clin Pharmacol. 2004 Sep;58(3):332-5 - PubMed
  18. Pharmacol Res. 2004 Aug;50(2):195-200 - PubMed
  19. Eur J Clin Pharmacol. 2003 Aug;59(4):303-12 - PubMed
  20. Pharmacogenetics. 1996 Jun;6(3):265-7 - PubMed
  21. Clin Pharmacol Ther. 2011 May;89(5):662-73 - PubMed
  22. Clin Exp Pharmacol Physiol. 2007 Jan-Feb;34(1-2):102-5 - PubMed
  23. Pharmacogenetics. 1999 Oct;9(5):581-90 - PubMed
  24. Nucleic Acids Res. 1988 Feb 11;16(3):1215 - PubMed
  25. Pharmacol Ther. 1993 Feb-Mar;57(2-3):129-60 - PubMed
  26. Lancet. 2009 Jan 24;373(9660):309-17 - PubMed
  27. Pharmacogenetics. 1995 Oct;5(5):312-7 - PubMed
  28. Clin Pharmacol Ther. 1998 Oct;64(4):391-401 - PubMed
  29. Pharmacogenomics. 2007 Sep;8(9):1199-210 - PubMed
  30. Clin Pharmacol Ther. 2007 Apr;81(4):521-8 - PubMed
  31. Eur J Clin Pharmacol. 1990;39(6):533-7 - PubMed
  32. Br J Clin Pharmacol. 2001 Oct;52(4):349-55 - PubMed
  33. Clin Pharmacol Ther. 1998 Oct;64(4):378-83 - PubMed
  34. Clin Pharmacol Ther. 1989 Aug;46(2):198-207 - PubMed
  35. N Engl J Med. 2009 Jan 22;360(4):354-62 - PubMed
  36. Clin Pharmacol Ther. 1999 May;65(5):552-61 - PubMed
  37. Mol Pharmacol. 1994 Oct;46(4):594-8 - PubMed
  38. Eur J Clin Pharmacol. 1998 Jul;54(5):427-30 - PubMed
  39. J Gastroenterol. 2001 Oct;36(10):669-72 - PubMed
  40. Pharmacol Rep. 2010 Jul-Aug;62(4):740-6 - PubMed
  41. Pharmacogenetics. 1997 Feb;7(1):59-64 - PubMed
  42. Fundam Clin Pharmacol. 2005 Feb;19(1):101-5 - PubMed
  43. Eur J Clin Pharmacol. 1998 Aug;54(6):479-81 - PubMed
  44. Pharmacogenetics. 1997 Aug;7(4):333-5 - PubMed
  45. Clin Pharmacol Ther. 2000 Sep;68(3):328-35 - PubMed
  46. Lancet. 1997 Mar 29;349(9056):921-2 - PubMed
  47. Clin Pharmacokinet. 1995 Sep;29(3):192-209 - PubMed
  48. J Intern Med. 2001 Sep;250(3):186-200 - PubMed
  49. Pharmacogenetics. 2001 Feb;11(1):69-76 - PubMed
  50. Clin Pharmacol Ther. 1984 Dec;36(6):773-80 - PubMed
  51. Clin Pharmacol Ther. 1999 Aug;66(2):185-92 - PubMed
  52. N Engl J Med. 2010 Oct 28;363(18):1704-14 - PubMed
  53. Biochemistry. 1994 Feb 22;33(7):1743-52 - PubMed
  54. Br J Clin Pharmacol. 1985 Apr;19(4):483-7 - PubMed
  55. Pharmacol Ther. 1989;43(1):53-76 - PubMed
  56. Br J Clin Pharmacol. 2002 Jun;53(6):596-603 - PubMed
  57. Pharmacogenetics. 1996 Dec;6(6):521-6 - PubMed
  58. Clin Pharmacol Ther. 1992 Apr;51(4):388-97 - PubMed
  59. Drug Metab Pharmacokinet. 2006 Aug;21(4):286-90 - PubMed
  60. Pharmacogenetics. 1996 Dec;6(6):547-51 - PubMed
  61. Clin Pharmacol Ther. 1999 Mar;65(3):275-82 - PubMed
  62. Eur J Clin Pharmacol. 2005 May;61(3):179-84 - PubMed
  63. Clin Pharmacol Ther. 1992 Aug;52(2):160-9 - PubMed

Publication Types